Is Rhythm Pharmaceuticals Stock a Good Investment?
Rhythm Pharmaceuticals Investment Advice | RYTM |
- Examine Rhythm Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Rhythm Pharmaceuticals' leadership team and their track record. Good management can help Rhythm Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Rhythm Pharmaceuticals' business and its evolving consumer preferences.
- Compare Rhythm Pharmaceuticals' performance and market position to its competitors. Analyze how Rhythm Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Rhythm Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Rhythm Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Rhythm Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Rhythm Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Rhythm Pharmaceuticals Stock
Researching Rhythm Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.75. Rhythm Pharmaceuticals recorded a loss per share of 4.32. The entity had not issued any dividends in recent years.
To determine if Rhythm Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Rhythm Pharmaceuticals' research are outlined below:
| Rhythm Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 77.43 M. Net Loss for the year was (184.68 M) with profit before overhead, payroll, taxes, and interest of 21.5 M. | |
| Rhythm Pharmaceuticals currently holds about 235.6 M in cash with (136.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.64. | |
| Rhythm Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data ... |
Rhythm Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Rhythm Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Rhythm Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Rhythm Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Rhythm Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-03-12 | 2017-12-31 | -0.46 | -0.41 | 0.05 | 10 | ||
2018-11-09 | 2018-09-30 | -0.46 | -0.52 | -0.06 | 13 | ||
2019-05-03 | 2019-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2021-11-02 | 2021-09-30 | -0.81 | -0.7 | 0.11 | 13 | ||
2020-03-02 | 2019-12-31 | -0.89 | -0.78 | 0.11 | 12 | ||
2020-08-03 | 2020-06-30 | -0.83 | -0.71 | 0.12 | 14 | ||
2018-05-14 | 2018-03-31 | -0.45 | -0.6 | -0.15 | 33 | ||
2019-03-08 | 2018-12-31 | -0.57 | -0.74 | -0.17 | 29 |
Know Rhythm Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Rhythm Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Rhythm Pharmaceuticals backward and forwards among themselves. Rhythm Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Rhythm Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rock Springs Capital Management Lp | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Driehaus Capital Management Llc | 2024-06-30 | 1.2 M | Alkeon Capital Management, Llc | 2024-09-30 | 1.2 M | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 951.3 K | Pictet Asset Manangement Sa | 2024-06-30 | 801.8 K | Orbimed Advisors, Llc | 2024-06-30 | 704.8 K | Checkpoint Capital Lp | 2024-09-30 | 663.4 K | Primecap Management Company | 2024-09-30 | 7.2 M | Blackrock Inc | 2024-06-30 | 6.7 M |
Rhythm Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.68 B.Market Cap |
|
Rhythm Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.57) | (0.60) | |
| Return On Capital Employed | (0.66) | (0.63) | |
| Return On Assets | (0.56) | (0.58) | |
| Return On Equity | (1.09) | (1.03) |
Determining Rhythm Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Rhythm Pharmaceuticals is a good buy. For example, gross profit margin measures Rhythm Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Rhythm Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Rhythm Pharmaceuticals' management efficiency
Rhythm Pharmaceuticals has return on total asset (ROA) of (0.4624) % which means that it has lost $0.4624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.479) %, meaning that it created substantial loss on money invested by shareholders. Rhythm Pharmaceuticals' management efficiency ratios could be used to measure how well Rhythm Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to grow to -0.63. At this time, Rhythm Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 24th of November 2024, Non Currrent Assets Other is likely to grow to about 16.1 M, while Other Current Assets are likely to drop about 5.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.94 | 2.97 | |
| Tangible Book Value Per Share | 2.82 | 2.94 | |
| Enterprise Value Over EBITDA | (15.39) | (16.16) | |
| Price Book Value Ratio | 15.62 | 16.40 | |
| Enterprise Value Multiple | (15.39) | (16.16) | |
| Price Fair Value | 15.62 | 16.40 | |
| Enterprise Value | 2.6 B | 2.7 B |
Understanding the operational decisions made by Rhythm Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 2.093 |
Basic technical analysis of Rhythm Stock
As of the 24th of November, Rhythm Pharmaceuticals holds the Semi Deviation of 2.54, coefficient of variation of 657.29, and Risk Adjusted Performance of 0.1244. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rhythm Pharmaceuticals, as well as the relationship between them. Please check Rhythm Pharmaceuticals market risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Rhythm Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 59.94 per share. Given that Rhythm Pharmaceuticals has jensen alpha of 0.2605, we recommend you to check out Rhythm Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.Rhythm Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rhythm Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rhythm Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rhythm Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rhythm Pharmaceuticals' Outstanding Corporate Bonds
Rhythm Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rhythm Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rhythm bonds can be classified according to their maturity, which is the date when Rhythm Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Understand Rhythm Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Rhythm Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1244 | |||
| Market Risk Adjusted Performance | 0.2572 | |||
| Mean Deviation | 2.55 | |||
| Semi Deviation | 2.54 | |||
| Downside Deviation | 3.01 | |||
| Coefficient Of Variation | 657.29 | |||
| Standard Deviation | 3.41 | |||
| Variance | 11.65 | |||
| Information Ratio | 0.1138 | |||
| Jensen Alpha | 0.2605 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1291 | |||
| Treynor Ratio | 0.2472 | |||
| Maximum Drawdown | 17.61 | |||
| Value At Risk | (4.90) | |||
| Potential Upside | 7.37 | |||
| Downside Variance | 9.06 | |||
| Semi Variance | 6.47 | |||
| Expected Short fall | (2.91) | |||
| Skewness | 0.6237 | |||
| Kurtosis | 1.03 |
| Risk Adjusted Performance | 0.1244 | |||
| Market Risk Adjusted Performance | 0.2572 | |||
| Mean Deviation | 2.55 | |||
| Semi Deviation | 2.54 | |||
| Downside Deviation | 3.01 | |||
| Coefficient Of Variation | 657.29 | |||
| Standard Deviation | 3.41 | |||
| Variance | 11.65 | |||
| Information Ratio | 0.1138 | |||
| Jensen Alpha | 0.2605 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1291 | |||
| Treynor Ratio | 0.2472 | |||
| Maximum Drawdown | 17.61 | |||
| Value At Risk | (4.90) | |||
| Potential Upside | 7.37 | |||
| Downside Variance | 9.06 | |||
| Semi Variance | 6.47 | |||
| Expected Short fall | (2.91) | |||
| Skewness | 0.6237 | |||
| Kurtosis | 1.03 |
Consider Rhythm Pharmaceuticals' intraday indicators
Rhythm Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Rhythm Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Rhythm Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify | |
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Rhythm Stock media impact
Far too much social signal, news, headlines, and media speculation about Rhythm Pharmaceuticals that are available to investors today. That information is available publicly through Rhythm media outlets and privately through word of mouth or via Rhythm internal channels. However, regardless of the origin, that massive amount of Rhythm data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Rhythm Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Rhythm Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Rhythm Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Rhythm Pharmaceuticals alpha.
Rhythm Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Rhythm Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Rhythm Pharmaceuticals Corporate Management
| Jennifer Lee | Executive America | Profile | |
| Yann Mazabraud | Executive International | Profile | |
| Christopher German | Principal Controller | Profile | |
| Sarah Ryan | Vice Marketing | Profile | |
| Jim Flaherty | Senior Counsel | Profile | |
| David Connolly | Head Communications | Profile | |
| Joseph Shulman | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Rhythm Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.